File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.pharmthera.2023.108417
- Scopus: eid_2-s2.0-85152748315
- PMID: 37075933
- WOS: WOS:000985904500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Detailed curriculum vitae of HER2-targeted therapy
| Title | Detailed curriculum vitae of HER2-targeted therapy |
|---|---|
| Authors | |
| Keywords | Cancer HER2 Inhibitor Resistance |
| Issue Date | 20-Apr-2023 |
| Publisher | Elsevier |
| Citation | Pharmacology and Therapeutics, 2023, v. 245 How to Cite? |
| Abstract | With the booming development of precision medicine, molecular targeted therapy has been widely used in clin-ical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of tra-ditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance. Here, a comprehensive overview of HER2 in numerous cancers is presented, including its biological role, involved signaling pathways, and the status of HER2-targeted therapy |
| Persistent Identifier | http://hdl.handle.net/10722/340041 |
| ISSN | 2021 Impact Factor: 13.400 2020 SCImago Journal Rankings: 3.461 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Zhang, XN | - |
| dc.contributor.author | Gao, Y | - |
| dc.contributor.author | Zhang, XY | - |
| dc.contributor.author | Guo, NJ | - |
| dc.contributor.author | Hou, WQ | - |
| dc.contributor.author | Wang, SW | - |
| dc.contributor.author | Zheng, YC | - |
| dc.contributor.author | Wang, N | - |
| dc.contributor.author | Liu, HM | - |
| dc.contributor.author | Wang, B | - |
| dc.date.accessioned | 2024-03-11T10:41:14Z | - |
| dc.date.available | 2024-03-11T10:41:14Z | - |
| dc.date.issued | 2023-04-20 | - |
| dc.identifier.citation | Pharmacology and Therapeutics, 2023, v. 245 | - |
| dc.identifier.issn | 0163-7258 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/340041 | - |
| dc.description.abstract | <p>With the booming development of precision medicine, molecular targeted therapy has been widely used in clin-ical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of tra-ditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance. Here, a comprehensive overview of HER2 in numerous cancers is presented, including its biological role, involved signaling pathways, and the status of HER2-targeted therapy</p> | - |
| dc.language | eng | - |
| dc.publisher | Elsevier | - |
| dc.relation.ispartof | Pharmacology and Therapeutics | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | Cancer | - |
| dc.subject | HER2 | - |
| dc.subject | Inhibitor | - |
| dc.subject | Resistance | - |
| dc.title | Detailed curriculum vitae of HER2-targeted therapy | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1016/j.pharmthera.2023.108417 | - |
| dc.identifier.pmid | 37075933 | - |
| dc.identifier.scopus | eid_2-s2.0-85152748315 | - |
| dc.identifier.volume | 245 | - |
| dc.identifier.isi | WOS:000985904500001 | - |
| dc.publisher.place | OXFORD | - |
| dc.identifier.issnl | 0163-7258 | - |